FS

Comprehensive Study Notes: Thyroid Hormones, Disorders, and Case-Based Management

Thyroid Hormones: Regulation, Disease, and Case-Based Management

1) Regulation of Thyroid Hormone Synthesis and Action

  • The thyroid axis operates via hypothalamic-pituitary-thyroid (HPT) feedback. The hypothalamus releases thyrotropin-releasing hormone (TRH), which stimulates the pituitary to release thyroid-stimulating hormone (TSH). TSH, in turn, stimulates the thyroid gland to synthesize and secrete thyroid hormones: thyroxine (T4) and triiodothyronine (T3).

    • Core feedback loop: TRH → TSH → T4/T3; circulating T4/T3 feedback to inhibit TRH and TSH release, maintaining homeostasis.
    • TSH is often the most sensitive marker for thyroid status; overt changes in TSH drive changes in T4/T3.

  • Thyroid hormones act by binding to nuclear thyroid hormone receptors, regulating gene transcription and producing widespread metabolic effects. Key pathways include:

    • Upregulation of Na+/K+-ATPase activity and mitochondrial activity, increasing basal metabolic rate (BMR).
    • Effects on CNS development and function, growth, and multiple organ systems.
    • Directional effects on heart rate, cardiac output, tissue blood flow, and respiration.

  • Hormone synthesis and presentation:

    • Thyroid follicular cells synthesize thyroglobulin, which is iodinated to form T3 and T4. These hormones are then stored bound in colloid until release.
    • Hormones circulate bound to transport proteins: predominantly thyroid hormone-binding globulin (TBG), with albumin and prealbumin also contributing. In plasma, only the free fractions, free T4 (FT4) and free T3 (FT3), are biologically active and capable of entering cells.
    • Local tissue activation/inactivation is regulated by deiodinase enzymes (see Deiodinases section).

  • Local transformation and regulation: the body controls intracellular T3 availability via deiodinase enzymes, ensuring tissue-specific hormone action independent of circulating levels. The major enzymes are:

    • Type I 5’-deiodinase (D1): liver, kidney, thyroid, pituitary, heart; contributes to peripheral T3 production.
    • Type II 5’-deiodinase (D2): pituitary, brain, skeletal muscle, brown adipose tissue; contributes to local T3 production near target tissues.
    • Type III 5’-deiodinase (D3): placenta, brain, skeletal muscle, fetal tissues; inactivates T4 to reverse T3 (rT3) and inactivates T3.
    • Overall function: local synthesis of T3 and regulation of local T3 production; inactivation of T3 to maintain appropriate intracellular levels.

2) Thyroid Hormone Transport and Plasma Dynamics

  • Free vs bound hormones:
    • Approximately 70% of T4 and 80% of T3 are bound to TBG; the remainder binds to albumin and pre-albumin.
    • Only the free fractions (FT4, FT3) are available to tissues; binding acts as a reservoir moderating fluctuations.
  • Transport and disposition: after release, thyroid hormones circulate bound, with small free fractions crossing cell membranes via transport proteins and acting on intracellular receptors to regulate transcription.

3) Normal Ranges and Laboratory Interpretation

  • Laboratory values commonly used:
    • Thyroid-stimulating hormone (TSH): reference range typically ~[0.3, 5.0] \, \text{mIU/L} (range may vary by assay and population).
    • Free T4 (FT4) and Free T3 (FT3) provide direct assessment of circulating active hormone.
    • In this material, examples include: TSH < 0.01 mIU/L with elevated FT4 indicating hyperthyroidism; TSH 8.5 mIU/L with low FT4 indicating hypothyroidism.
  • When diagnosing subclinical states:
    • Subclinical hyperthyroidism: suppressed TSH with normal FT4/FT3.
    • Subclinical hypothyroidism: elevated TSH with normal FT4/FT3.

4) Hypothyroidism: Causes, Presentation, Diagnosis, and Management

  • Signs and symptoms (effect across organ systems):
    • Appearance: puffy face; loss of eyebrows.
    • Metabolic: weight gain; fatigue; cold intolerance; constipation; dry skin; hair thinning.
    • Neurological/psychological: cognitive slowing, depression, slowed speech.
    • Cardiovascular: bradycardia; diastolic hypertension; reduced cardiac output in severe disease.
    • Reproductive: irregular/heavy menses; reduced libido; subfertility.
    • Extremities: peripheral neuropathy or paresthesias; brittle nails.
  • Common causes (global themes):
    • Hashimoto's thyroiditis (autoimmune destruction) is a leading cause in many adults.
    • Postpartum thyroiditis can occur, and iodine deficiency can contribute in endemic areas.
    • Drug-related and infiltrative processes can also cause hypothyroidism.
  • Case 2 (John Smith) presentation aligns with primary hypothyroidism:
    • Symptoms: fatigue, weight gain, cold intolerance, constipation, dry skin, hair thinning, cognitive slowing; hoarse voice; mild edema; overweight.
    • Lab pattern: TSH elevated (e.g., 8.5 mIU/L) with low FT4.
    • Diagnosis: primary hypothyroidism, likely Hashimoto's thyroiditis.
  • Diagnostic confirmation:
    • Check for thyroid antibodies: thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (TgAb).
  • Pathophysiology behind bradycardia in hypothyroidism:
    • Reduced metabolic rate leads to decreased cardiac output and slowed heart rate due to insufficient thyroid hormone action on the cardiovascular system.
  • Complications if untreated:
    • Myxedema coma, heart failure (bradycardia/low output), depression, cognitive impairment, hyperlipidemia with increased cardiovascular risk.
  • Standard treatment:
    • Levothyroxine (synthetic LT4) replacement therapy, dosed to normalize TSH and FT4.
    • Typical starting guidelines (adjust by age, comorbidity): large-scale guideline references show LT4 can be started at around 1.6\ \mu g/kg/day in adults, with lower starting doses (e.g., 1.0\ \mu g/kg/day) in elderly or cardiovascular disease, and titration every 6 weeks until TSH normal.
    • In pregnancy, LT4 dose often increases ~30\% to maintain euthyroidism for fetal development.
  • Dosing and monitoring details:
    • Initiation: LT4 at 1.6\ \mu g/kg/day for adults without confounders.
    • Monitoring: recheck TSH and FT4 every 6-8 weeks after initiation or dose change, then every 6-12 months once stable.
    • Absorption considerations: LT4 absorption is affected by food and certain medications; take on an empty stomach 30-60 minutes before breakfast; avoid taking LT4 with calcium, iron, certain antacids, PPIs, or other interfering drugs.

5) Hyperthyroidism: Causes, Presentation, Diagnosis, and Management

  • Signs and symptoms (system-wide “faster everything”):
    • Weight loss with increased appetite, heat intolerance, sweating, tremor, anxiety, irritability, insomnia, palpitations, tachycardia, hypertension, diarrhea, brisk reflexes.
    • Hair and nail changes (fine hair, hyperdynamic circulation).
  • Primary causes (high-yield categories):
    • Graves' disease (autoimmune stimulation of TSH receptor).
    • Toxic multinodular goiter or toxic solitary nodule.
    • TSH receptor-stimulating antibodies and/or high TSH receptor antibody (TRAb).
    • Elevated T3/T4 with suppressed TSH; HCG excess in early pregnancy can also mimic hyperthyroidism.
  • Case 1 (Sarah Johnson) presentation and reasoning:
    • Symptoms: fatigue, weight loss, palpitations, heat intolerance, sweating, anxiety, sleep disturbance, irregular menses; exam shows mild goiter; vitals show tachycardia; labs: suppressed TSH with elevated FT4.
    • Most likely diagnosis: hyperthyroidism, Graves' disease likely, given the symptom constellation and goiter with a suppressed TSH and elevated FT4.
    • Additional diagnostic tests to confirm Graves' disease: thyroid-stimulating immunoglobulin (TSI) or thyroid peroxidase antibodies (TPO-Ab); radioactive iodine uptake (RAIU) scan to differentiate etiologies.
  • Mechanisms behind tachycardia in hyperthyroidism:
    • Thyroid hormones increase adrenergic receptor density and sensitivity (upregulation of β-adrenergic receptors), leading to increased heart rate and contractility and enhanced cardiac output.
  • Potential complications if untreated:
    • Thyroid storm (thyrotoxic crisis), atrial fibrillation, osteoporosis, myopathy, heart failure due to sustained tachycardia.
  • First-line treatment options for hyperthyroidism:
    • Antithyroid drugs (thionamides): methimazole (or carbimazole, neomercazole) or propylthiouracil (PTU, typically avoided in SA except specific contexts); these inhibit thyroid hormone synthesis.
    • Radioactive iodine therapy (RAI).
    • Thyroidectomy (surgery) when indicated (e.g., large goiter, suspicion of malignancy, relapse, or intolerance/relativity to other therapies).
    • Beta-blockers (e.g., propranolol, atenolol, metoprolol) to control adrenergic symptoms (tachycardia, tremor).
    • In the context of a thyroid storm, a multi-pronged approach including thionamides, beta-blockade, inorganic iodide (after thionamide), glucocorticoids, and supportive care is recommended.
  • Medication notes and safety:
    • Methimazole/carbimazole are preferred in many adults; PTU has a role in thyroid storm and in first-trimester pregnancy due to teratogenicity concerns with methimazole.
    • Agranulocytosis is a rare but serious adverse effect; baseline and periodic WBC checks may be considered if symptoms suggest infection.
    • In pregnancy, levothyroxine dose adjustments may be needed due to maternal-fetal metabolic demands.
  • Dosing and monitoring for hyperthyroidism management:
    • Beta-blockers: standard dosing examples include propranolol 10-40 mg three to four times daily; alternatives include atenolol, metoprolol, nadolol, or esmolol in ICU settings.
    • Thionamides: PTU 500-1000 mg loading dose, then 250 mg every 4 hours; methimazole 20 mg every 4-6 hours (adjust for severity and pregnancy).
    • In thyroid storm, iodine (Lugol's solution or potassium iodide) is given about 1 hour after thionamide to block thyroid hormone release; hydrocortisone 100 mg IV every 8 hours (or dexamethasone 2 mg IV every 6 hours) helps reduce peripheral conversion of T4 to T3 and provides adrenal support.
    • Glucocorticoids also help stabilize hemodynamics in thyroid storm and mitigate inflammatory processes.
  • Diagnostic tests and imaging in hyperthyroidism:
    • RAIU (radioactive iodine uptake) helps differentiate Graves' disease, toxic multinodular goiter, and thyroiditis.
    • Ultrasound and scintigraphy are used to evaluate thyroid architecture and function when indicated.

6) Diagnostic Tests, Imaging, and Special Tests

  • Laboratory tests:
    • TSH, FT4, FT3 for baseline thyroid status.
    • Autoimmune antibodies: TPO-Ab, TgAb; TSI (TSH receptor antibody) primarily used to support Graves' disease diagnosis.
  • Imaging:
    • Ultrasound for structure and nodules; scintigraphy/RAIU for functional assessment to distinguish Graves', toxic nodules, and thyroiditis.
    • In the evaluation of thyroid emergencies, imaging helps guide management decisions and surgical planning.

7) Subacute Thyroiditis and Postpartum Thyroiditis

  • Subacute thyroiditis (SAT):
    • Typically presents with neck pain and tender thyroid; transient thyrotoxicosis followed by hypothyroidism and eventual recovery.
    • Management depends on severity: NSAIDs and beta-adrenergic blockers for thyrotoxic symptoms; corticosteroids for moderate to severe pain or thyrotoxic symptoms; levothyroxine may be used during the hypothyroid phase.
  • Postpartum thyroiditis and other forms of SAT are included in the spectrum of subacute inflammatory thyroid disorders.

8) Subclinical Hyperthyroidism and Subclinical Hypothyroidism: Management Nuances

  • Subclinical hyperthyroidism:
    • Low TSH with normal FT4/FT3.
    • Management decisions depend on age, cardiovascular and skeletal risk factors, and symptoms. In elderly patients or those at high risk of atrial fibrillation or osteoporosis, treatment may be considered or closer monitoring performed.
  • Subclinical hypothyroidism:
    • Elevated TSH with normal FT4/FT3.
    • Decisions to treat depend on TSH level, symptoms, age, pregnancy status, and comorbidities. In general, LT4 replacement is considered if TSH is persistently elevated with symptoms or in risk scenarios.

9) Thyroid Emergencies: Thyroid Storm and Myxedema (Myxedema) Coma

  • Thyroid Storm (thyrotoxicosis crisis):
    • A life-threatening, decompensated hyperthyroid state with multi-organ involvement.
    • Diagnostic features: elevated FT3/FT4 with undetectable or suppressed TSH; CNS symptoms (agitation, delirium, psychosis), fever, tachycardia, heart failure, GI/hepatic manifestations.
    • Management (multimodal): beta-blocker (to control adrenergic symptoms), thionamides (to inhibit new hormone synthesis), inorganic iodide after thionamide to block release, glucocorticoids (to reduce conversion and provide adrenal support), supportive care, treatment of precipitating factors, and consideration of ICU admission.
    • If surgery is required, pretreatment with beta-blockers, glucocorticoids, and iodine is essential.
  • Myxedema (Myxedema coma):
    • A severe, decompensated hypothyroid state with high mortality if untreated.
    • Management highlights (ED/ICU): IV thyroxine replacement, hydrocortisone (to cover possible adrenal insufficiency until ruled out), aggressive supportive care (fluids, warming, O2), treatment of precipitating factors, and consideration of thyroidectomy only in rare, controlled cases.
    • Therapeutic routes in myxedema coma involve a combination of thyroid hormone replacement (T4 with or without T3), hydrocortisone, and supportive treatments.

10) Pharmacology Essentials: Antithyroid Drugs, Iodine, Beta-Blockers, and Adverse Effects

  • Antithyroid drugs (thionamides):
    • Methimazole (MMI) / Carbimazole / Neomercazole: inhibits thyroid hormone synthesis; dosing varies by severity and pregnancy status.
    • Propylthiouracil (PTU): inhibits synthesis and also peripheral conversion of T4 to T3; preferred in thyroid storm and in the first trimester of pregnancy (specialist consultation recommended).
    • Common adverse effects: pruritus, rash, urticaria, arthralgia, fever; serious but rare agranulocytosis (monitor for sore throat, fever); hepatotoxicity concerns (especially with PTU).
  • Beta-blockers:
    • Used to control adrenergic symptoms (tachycardia, tremor, anxiety) in hyperthyroidism and thyroid storm.
    • Examples include propranolol, atenolol, metoprolol, nadolol; dosing varies by agent and clinical status.
  • Iodine and radioiodine:
    • Inorganic iodine (e.g., Lugol's solution, potassium iodide) blocks thyroid hormone release when given after thionamides (to prevent new hormone synthesis).
    • Radioactive iodine (RAI) therapy is a definitive treatment for Graves’ disease and toxic nodules but contraindicated in pregnancy and certain eye diseases related to Graves’ orbitopathy.
  • Glucocorticoids:
    • Used to reduce T4-to-T3 conversion and to provide hemodynamic support in thyroid storm; also used if adrenal insufficiency is suspected.

11) Diagnosis and Management Strategy: Key Practical Points

  • Case-based interpretation highlights:

    • Case 1 (Sarah Johnson) suggests Graves' disease with hyperthyroidism: suppressed TSH, elevated FT4. Confirm with TSI or TPO-Ab; differentiate with RAIU scan if needed; treat with antithyroid drugs, beta-blockers for symptoms, and consider definitive therapy (RAI or surgery) based on patient factors.
    • Case 2 (John Smith) demonstrates primary hypothyroidism: elevated TSH with low FT4, likely Hashimoto's thyroiditis. Confirm with TPO-Ab and TgAb; treat with levothyroxine, monitor TSH and FT4, and adjust dose with age and comorbidities.

  • General treatment framework (contrast hyper- vs hypothyroid):

    • Hyperthyroidism: symptom control with beta-blockers; inhibit synthesis with thionamides; consider iodine blockade; definitive options include RAI or thyroidectomy; monitor thyroid function tests and adjust therapy.
    • Hypothyroidism: replacement with levothyroxine; titrate dose to achieve target TSH; monitor for age-related factors and pregnancy requirements; ensure absorption is optimized (empty stomach, timing around meals and interfering medications).

12) Practical Considerations and Common Interactions

  • Levothyroxine administration and interactions:
    • Take LT4 on an empty stomach 30-60 minutes before breakfast.
    • Do not take LT4 with calcium, iron, PPIs, antacids, or other agents that impair absorption.
    • Pregnant patients may require higher LT4 doses; monitor TSH and FT4 closely.
  • Absorption barriers (dietary and medical):
    • Calcium, iron supplements, laxatives, certain antacids, and some GI conditions (celiac disease, lactose intolerance, atrophic gastritis, pancreatic insufficiency, inflammatory bowel disease) can reduce LT4 absorption and affect therapeutic response.
  • Drug-induced thyroid effects: Lithium can cause goiter and hypothyroidism; monitoring is advised when used chronically.

13) Key Distinctions and Quick References

  • Graves' disease vs Hashimoto's thyroiditis:
    • Graves' disease: autoimmune stimulation of TSH receptor → hyperthyroidism; TSH suppressed; TSI positive; potential Graves' orbitopathy.
    • Hashimoto's thyroiditis: autoimmune destruction of thyroid gland → hypothyroidism; TPO-Ab and TgAb positive; goiter may be present.
  • Diagnostic anchors:
    • Hyperthyroid pattern: low TSH, high FT4/FT3; symptoms of thyrotoxicosis; possible diffuse goiter.
    • Hypothyroid pattern: high TSH, low FT4; symptoms of hypothyroidism; possible non-tender goiter.

14) Summary Concepts (Recap)

  • Thyroid hormones accelerate metabolism and organ function; hypothyroidism slows metabolism, while hyperthyroidism accelerates it.
  • Regulation hinges on negative feedback via TSH, TRH, and T4/T3 levels, with tissue-specific regulation via deiodinases (D1, D2, D3).
  • Diagnostic approach combines labs (TSH, FT4, FT3, autoantibodies) with imaging (ultrasound, RAIU) to determine etiology and guide therapy.
  • Treatment aims differ by condition but share core principles: address symptoms, correct hormone imbalances, mitigate complications, and consider patient-specific factors (pregnancy, age, comorbidities).

15) References to Specific Values and Tables (LaTeX-ready)

  • Normal ranges and values observed in this transcript:
    • TSH: 0.3 \leq \text{TSH} \leq 5.0 \text{ mIU/L} (typical reference range; exact values may vary by assay).
    • Case 1 example: \text{TSH} < 0.01 \text{ mIU/L}, \quad \text{Free } T4 \text{ elevated}.
    • Case 2 example: \text{TSH} = 8.5 \ \text{mIU/L}, \quad \text{Free } T4 \text{ low}.
  • Thyroid hormone replacement dosing (examples):
    • Start LT4 at 1.6\ \mu\text{g/kg/day} in adults; adjust for age/comorbidities.
    • In older patients or with cardiovascular disease, consider 1.0\ \mu\text{g/kg/day} with slower titration.
    • Pregnancy: LT4 dose often increases ~+30\%.

16) Connections to Foundational Principles and Real-World Relevance

  • The material connects foundational physiology (HPT axis, negative feedback, hormone receptor action) to clinical practice (diagnosis and management of hyper- and hypothyroidism).
  • Ethical and practical implications include ensuring appropriate management in pregnancy (fetal development), addressing the risks of antithyroid drugs (agranulocytosis, hepatotoxicity), and choosing definitive therapy (RAI vs surgery) in Graves' disease while considering patient preferences and comorbidities.
  • Recognition of emergencies (thyroid storm, myxedema coma) highlights the need for rapid, multidisciplinary, ICU-level care and adherence to evidence-based treatment algorithms.